Most hydrogen research that reaches consumers is small, preliminary, or done in animals. The COPD literature is an exception in one specific respect: there is a genuinely large, genuinely randomized, genuinely double-blind trial, run across ten centres, testing inhaled hydrogen against the standard of care during a COPD flare-up[1]. That makes it worth reading closely, including the parts of the result that were negative.
It also comes with a distinction that matters more than anything else on this page: the trial tested a hydrogen and oxygen gas mixture delivered by a medical device in hospital. It did not test hydrogen water, hydrogen tablets, or anything a person buys for home use.
What the trial actually tested
The study enrolled patients experiencing an acute exacerbation of chronic obstructive pulmonary disease, the medical term for a COPD flare-up, at ten centres[1]. To be eligible, patients needed a Breathlessness, Cough, and Sputum Scale score of at least 6 points, which screens out people whose symptoms were mild at baseline and would have little room to improve.
Patients were randomly assigned in a one-to-one ratio to receive either the hydrogen and oxygen mixture or oxygen therapy alone. Both patients and investigators were blinded. The primary endpoint was the change from baseline in that breathlessness, cough and sputum score at day 7.
That design detail is worth pausing on. The comparison was not hydrogen versus nothing, and not hydrogen versus a sugar pill. It was hydrogen plus oxygen versus oxygen, which is the actual treatment a patient would otherwise receive. Trials that beat an active comparator are harder to win than trials that beat a placebo.
The symptom results
On the primary endpoint, the hydrogen and oxygen group improved by 5.3 points on the breathlessness, cough and sputum scale, against 2.4 points in the oxygen-only group[1]. The difference was 2.75 points, with a 95 percent confidence interval running from 3.27 to 2.22, and it met the trial’s pre-specified criteria for superiority.
A confidence interval that sits entirely away from zero, and that is fairly narrow, is a stronger signal than a bare p-value. It means the plausible range of the true effect does not include “no difference at all.”
The pattern was not confined to the final measurement. Similar results were observed at every time point from day 2 through day 6, which argues against the day 7 result being a fluke of a single measurement day.
Cough was measured separately using the Cough Assessment Test, and the hydrogen group improved by 11.00 points against 6.00 points for oxygen alone, at p less than 0.001[1].
What the score being measured actually captures
The Breathlessness, Cough, and Sputum Scale is a patient-reported instrument with three components, one for each of the symptoms in its name. A patient rates each one, and the ratings sum to a total. The trial required a score of at least 6 at entry[1], which places participants well into symptomatic territory.
An improvement of 5.3 points against 2.4 points means the hydrogen group’s symptom burden fell by roughly twice as much over the same seven days. Because the scale is bounded and each component contributes only a few points, a 2.75-point separation is a large fraction of the available range rather than a marginal shift.
The fact that the instrument is patient-reported is both its strength and its weakness. Its strength is that it measures the thing patients care about, which is how bad the flare-up feels. Its weakness is that it depends on self-report, so blinding is what protects the result. This trial was double-blind, which is the appropriate safeguard, and both arms were breathing gas through a device, which makes the blinding credible in a way a pill-versus-nothing design would not.
The results that did not go hydrogen’s way
This is the part that supplement marketing tends to leave out, and it is the part that most changes how the trial should be read.
Changes in pulmonary function did not differ significantly between the groups. Neither did arterial blood gas measurements. Neither did noninvasive oxygen saturation[1]. The trial’s other endpoints likewise showed no significant separation.
So the honest summary is narrower than “hydrogen treats COPD flare-ups.” Patients breathing the hydrogen and oxygen mixture felt substantially better, and coughed substantially less, than patients breathing oxygen alone. The objective measures of how well their lungs were moving air, and how much oxygen was reaching their blood, looked the same in both groups.
Both of those things can be true simultaneously, and neither cancels the other. Symptom burden during a flare-up is a real outcome that matters to patients living through one. But a symptom improvement without a matching change in lung mechanics means the mechanism is not established, and it means the trial does not show hydrogen altering the underlying disease process.
What the safety data showed
Adverse events were reported in 34 patients, or 63.0 percent, in the hydrogen and oxygen group, and in 42 patients, or 77.8 percent, in the oxygen group[1]. No deaths occurred during the study period, and no equipment defects were reported.
Adverse event rates above 60 percent in both arms sound alarming out of context. In a hospitalised population experiencing an acute respiratory exacerbation, a high background rate of recorded events is expected, and the relevant comparison is between arms rather than against zero. On that comparison, the hydrogen arm did not look worse.
The trial was registered as NCT04000451, with a registration date of 27 June 2019, and the publication notes that registration was retrospective[1]. Retrospective registration is a real methodological weakness. Prospective registration is what prevents endpoints from being chosen after the data are seen, so its absence removes one of the safeguards a reader would otherwise rely on.
Why hydrogen was tested here at all
The rationale traces back to the 2007 paper that started the modern field, which proposed that molecular hydrogen acts as a selective antioxidant, reducing particularly damaging oxygen radicals rather than suppressing reactive species indiscriminately[2]. COPD involves substantial oxidative stress in airway tissue, so a selective antioxidant delivered directly to the airway is at least a coherent hypothesis.
There is also supporting animal work in lung tissue specifically. Inhaled hydrogen gas was tested for prevention of lung transplant-induced ischemia and reperfusion injury in rats[3]. That is a different injury model from a COPD exacerbation, and a rat is not a person, so it supports plausibility rather than efficacy.
Symptom relief without measurable mechanism change
The combination of a clear symptom benefit and flat objective measures is not unusual in respiratory medicine, and there are several explanations that the trial cannot distinguish between.
One possibility is that the effect is real but works on something the trial did not measure. Cough and breathlessness are mediated partly by airway irritation and sensory nerve signalling, which spirometry and blood gases do not capture. A treatment reducing airway irritation could plausibly reduce cough without changing how much air the lungs move.
A second possibility relates to the gas mixture itself. Hydrogen has very low density compared with the nitrogen it displaces, and low-density gas mixtures are easier to move through narrowed airways. If part of the benefit came from that physical property rather than from hydrogen’s biochemical activity, the antioxidant framing would be the wrong explanation for a real effect.
A third possibility is that the difference reflects residual unblinding or measurement noise in a patient-reported outcome. The consistency of the effect from day 2 through day 6[1] argues against pure noise, but a single trial cannot rule it out.
The trial was not designed to separate these, and its authors did not claim to have done so. Anyone citing it as evidence that hydrogen’s antioxidant mechanism treats COPD is asserting something the data do not establish.
What a confirmatory trial would need
The gap between this result and a change in practice is specific enough to describe.
- Prospective registration, which this trial lacked, so that endpoint selection is locked before the data are seen.
- An independent research group and population, since replication by the same investigators in the same setting answers a narrower question.
- A control for gas density, comparing hydrogen against an inert low-density mixture rather than only against oxygen, to separate the physical explanation from the biochemical one.
- Outcomes past day 7, including time to readmission and exacerbation recurrence, which determine whether short-term symptom relief translates into anything durable.
What this does not mean
Several conclusions do not follow from this trial, and it is worth stating them explicitly because they are the ones most likely to be assumed.
- It does not apply to hydrogen water or tablets. The intervention was an inhaled hydrogen and oxygen gas mixture from a medical device. Nothing in this trial tests whether drinking hydrogen-rich water does anything for COPD.
- It does not apply to stable COPD. Every participant was in an acute exacerbation. The trial says nothing about day-to-day management between flare-ups.
- It does not replace anything. The hydrogen arm received hydrogen in addition to oxygen therapy. It was tested as an addition to care, not as a substitute for inhalers, oxygen, or any prescribed treatment.
- It is one trial. A single multicentre trial, however well constructed, is not a body of evidence. Independent replication has not been established.
What a person with COPD should take from it
If you have COPD, the useful reading is that hydrogen and oxygen therapy has one credible randomised trial behind it for symptom relief during exacerbations, that it was studied as a hospital-delivered gas therapy alongside standard oxygen, and that its effect on measured lung function in that trial was indistinguishable from oxygen alone.
That is a reasonable thing to raise with a pulmonologist. It is not a reason to buy a consumer hydrogen device, because consumer devices were not what was tested, and it is emphatically not a reason to alter or delay any prescribed treatment during a flare-up. A COPD exacerbation is a medical event, and the decision-making around one belongs with the clinician managing it.
References
- Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial. Respiratory Research, 2021
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine, 2007
- Inhaled hydrogen gas therapy for prevention of lung transplant-induced ischemia/reperfusion injury in rats. Transplantation, 2010
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
